Clinical characteristics of varian cancer patients with survival time over 3 years and its influencing factors of prognosis
-
摘要:目的 探讨生存期超过3年的卵巢癌患者的临床特征及其预后相关影响因素。方法 回顾性分析87例卵巢癌患者的病例资料，探讨患者的临床特征及影响预后的相关影响因素。结果 87例卵巢癌患者的平均年龄为(52.58±10.23)岁，按照生存时间分为生存时间>3年组及生存时间≤3年组。生存时间>3年组共54例，其中17例死亡，存活37例; 生存时间≤3年组共33例，其中22例死亡，存活11例。同时剔除了生存期≤3年仍然存活者11例，共76例患者纳入后续研究。通过Kaplan-Meier法及Cox多因素对预后影响因素进行分析，结果表明手术、临床分期、初诊卡氏功能状态评分(KPS评分)、化疗周期、中药使用时间是影响卵巢癌患者预后的独立因素。结论 早期诊断，彻底的手术治疗，规范、足量及多疗程的化疗，合理配合中医药治疗，是提高卵巢癌患者生存率的关键。Abstract:Objective To explore the clinical characteristics of varian cancer patients with survival time over 3 years with and its influencing factors of prognosis.Methods The clinical data of 87 patients with ovarian malignancy were analyzed retrospectively, and the clinical characteristics and its influencing factors of prognosis were observed.Results The average age of 87 patients with ovarian cancer was (52.58±10.23) years old. According to the survival time, they were divided into the survival time >3 years group (n=54) including 17 deaths and 37 survival patients and the survival time ≤3 years group (n=33) including 22 deaths and 11 survival patients. At last, a total of 76 patients were included in the study except for 11 survival patients with survival time ≤3 years. Kaplan-Meier survival analysis and Cox multiple factor survival analysis showed that operation, clinical staging, Karnofsky function and status(KPS) scores, cycles of chemotherapy, the use of traditional Chinese medicine were the prognostic factors of patients with ovarian cancer.Conclusion Early diagnosis, operation treatment thoroughly, specification, sufficient and multiple courses of chemotherapy, combined with traditional Chinese medicinal treatment can prolong the survival time of patients with ovarian cancer.
-
Keywords:
- ovarian cancer /
- clinical characteristics /
- prognosis /
- survival time
-
-
表 1 2组患者临床资料及治疗情况比较[n(%)]
指标 n 生存期>3年组 生存期≤3年组 χ2 P值 手术 是 54 52(96.30) 2(9.09) 57.80 < 0.01 否 22 2(3.70) 20(90.91) 临床分期 Ⅰ~Ⅱ期 21 20(37.04) 1(4.55) 8.25 < 0.01 Ⅲ~Ⅳ期 55 34(62.96) 21(95.45) 化疗周期/个 ≥8 36 32(59.26) 4(18.18) 11.01 < 0.01 < 8 40 22(40.74) 18(81.82) 初诊KPS评分/分 ≥60 54 46(85.19) 8(36.36) 18.11 < 0.01 < 60 22 8(14.81) 14(63.64) 使用中药/月 >12 32 28(51.85) 4(18.18) 31.74 < 0.01 6~12 26 18(33.33) 8(36.36) < 6 18 8(14.81) 10(45.45) 年龄/岁 < 60 56 40(74.07) 16(72.73) 0.01 >0.05 ≥60 20 14(25.93) 6(27.27) 放疗 是 9 6(11.11) 3(13.64) 0.01 >0.05 否 67 48(88.89) 19(86.36) 
下载: 导出CSV
表 2 卵巢癌患者预后多因素分析结果
影响因素 β值 SE Wald RR P值 手术 2.135 0.523 15.948 8.726 < 0.01 临床分期 -0.855 0.316 7.258 0.412 < 0.01 化疗周期 -0.623 0.291 5.486 1.875 < 0.05 初诊KPS -0.878 0.287 7.124 2.193 < 0.01 使用中药时间 -0.336 0.154 5.287 1.256 < 0.01
下载: 导出CSV
-
[1] Matulonis U A. Management of newly diagnosed or recurrent ovarian cancer[J]. Clin Adv Hematol Oncol, 2018, 16(6): 426-437. http://www.ncbi.nlm.nih.gov/pubmed/30067614
[2] Kim J Y, Cho C H, Song H S. Targeted therapy of ovarian cancer including immune check point inhibitor[J]. Korean J Intern Med, 2017, 32(5): 798-804. doi: 10.3904/kjim.2017.008
[3] Dong X, Men X, Zhang W, et al. Advances in tumor markers of ovarian cancer for early diagnosis[J]. Indian J Cancer, 2014, 51(Suppl 3): e72-e76. http://www.ncbi.nlm.nih.gov/pubmed/25818738
[4] Heidemann L N, Hartwell D, Heidemann C H, et al. The relation between endometriosis and ovarian cancer-a review[J]. Acta Obstet Gynecol Scand, 2014, 93(1): 20-31. doi: 10.1111/aogs.12255
[5] 林洪生. 恶性肿瘤中医诊疗指南[M]. 北京: 人民卫生出版社, 2014: 448-448. [6] 卢淮武, 林仲秋. 2018 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南[J]. 中国实用妇科与产科杂志, 2018, 34(5): 526-536. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF201805016.htm [7] Jiang Y H, He W F, Yang H, et al. Analysis of clinical effects of neoadjuvant chemotherapy in advanced epithelial ovarian cancer[J]. J BUON, 2018, 23(3): 758-762. http://www.ncbi.nlm.nih.gov/pubmed/30003748
[8] Moufarrij S, Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: promise and progress[J]. Clin Epigenetics, 2019, 11(1): 7-17. doi: 10.1186/s13148-018-0602-0
[9] Bommert M, Harter P, Heitz F, et al. When should surgery be used for recurrent ovarian carcinoma[J]. Clin Oncol (R Coll Radiol), 2018, 30(8): 493-497. doi: 10.1016/j.clon.2018.04.006
[10] Ben-Arye E, Lavie O, Samuels N, et al. Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a "bedside-to-bench" approach[J]. Med Oncol, 2017, 34(4): 54-54. doi: 10.1007/s12032-017-0910-9
[11] 刘新敏, 朴炳奎. 朴炳奎治疗卵巢癌经验[J]. 中医杂志, 2015, 56(22): 1907-1909. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201522007.htm [12] 黄宏, 沈敏鹤, 阮善明, 等. 吴良村治疗卵巢癌经验[J]. 中医杂志, 2017, 58(9): 737-740. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201709005.htm [13] 李平. 对肿瘤病因、致病特点的再认识[J]. 中国中西医结合杂志, 2018, 38(2): 160-162. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201802008.htm -
期刊类型引用(8)
1. 杨增芯，李伟章，翁玉龙，陈兵，陆鑫. 沙库巴曲缬沙坦对COPD合并心力衰竭患者心功能的影响. 临床合理用药. 2025(01): 1-3+7 . 
百度学术
2. 刘媛，王澎，聂静. 血清BNP、CRP、PCT水平对慢阻肺急性加重期患者并发心力衰竭的预测价值. 航空航天医学杂志. 2024(03): 270-273 . 百度学术
3. 周蓓，邱饶元. 慢性阻塞性肺疾病急性发作合并心力衰竭患者使用那屈肝素的临床效果研究. 现代诊断与治疗. 2024(13): 1932-1934+1966 . 百度学术
4. 冯双喜，袁天舒，林惠霞，伍利群. 不同标本类型中超敏C反应蛋白检验结果在脑瘫儿童感染性疾病治疗中的一致性分析. 中国医药指南. 2024(33): 41-43 . 百度学术
5. 康林，祝莹，高芸，黄瑾，李润洁. 血清降钙素、脑钠肽、心肌肌钙蛋白Ⅰ与老年肺炎病情严重程度的关系. 实用临床医药杂志. 2023(17): 93-96 . 本站查看
6. 缪雄，吉鹏，钱晶，陆洋. 低分子肝素联合卡维地络对COPD合并心力衰竭患者心肺功能和相关指标的影响. 中南医学科学杂志. 2022(05): 732-735 . 百度学术
7. 汪晶，彭博，王海存，崔晶，谭立业. 超滤联合注射用益气复脉治疗难治性心力衰竭的效果. 中国当代医药. 2022(28): 92-95 . 百度学术
8. 王小荣. 伊伐布雷定在COPD合并心力衰竭患者临床应用分析. 中外医疗. 2021(18): 94-97 . 百度学术
其他类型引用(1)
计量
- 文章访问数: 495
- HTML全文浏览量: 151
- PDF下载量: 11
- 被引次数: 9
苏公网安备 32100302010246号
